(Q31155365)

29 June 2017

1 reference

title

Pharmacokinetic and pharmacodynamic data to be derived from early-phase drug development: designing informative human pharmacology studies (English)

1 reference

29 June 2017

1 reference

1 reference

1 reference

Adam Cohen

1

1 reference

29 June 2017

publication date

1 January 2008

1 reference

Clinical Pharmacokinetics

29 June 2017

published in

1 reference

29 June 2017

volume

47

1 reference

29 June 2017

issue

6

1 reference

29 June 2017

page(s)

373-381

1 reference

https://scigraph.springernature.com/pub.10.2165/00003088-200847060-00002

29 June 2017

exact match

0 references

cites work

Integrated pharmacokinetics and pharmacodynamics of Ro 48-8684, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects

1 reference

12 December 2020

Sudden death of a volunteer

1 reference

12 December 2020

Pharmacokinetic/pharmacodynamic assessment of tolerance to central nervous system effects of a 3 mg sustained release tablet of rilmenidine in hypertensive patients.

1 reference

12 December 2020

Tolrestat pharmacokinetic and pharmacodynamic effects on red blood cell sorbitol levels in normal volunteers and in patients with insulin-dependent diabetes

1 reference

12 December 2020

Postmarketing drug dosage changes of 499 FDA-approved new molecular entities, 1980-1999.

1 reference

12 December 2020

Establishing risk of human experimentation with drugs: lessons from TGN1412.

1 reference

12 December 2020

Effect of an NK1/NK2 receptor antagonist on airway responses and inflammation to allergen in asthma

1 reference

12 December 2020

Impact of pharmacometric reviews on new drug approval and labeling decisions--a survey of 31 new drug applications submitted between 2005 and 2006.

1 reference

12 December 2020

Clinically significant adverse effects in a Phase 1 testing program

1 reference

12 December 2020

Joining the DoTS: new approach to classifying adverse drug reactions

1 reference

12 December 2020

Impact of pharmacometrics on drug approval and labeling decisions: a survey of 42 new drug applications

1 reference

12 December 2020

"Getting the dose right": facts, a blueprint, and encouragements

1 reference

12 December 2020

Pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor ximelagatran in young healthy Japanese men.

1 reference

12 December 2020

Evaluation of a vaporizing device (Volcano) for the pulmonary administration of tetrahydrocannabinol.

1 reference

12 December 2020

Radioligand studies: imaging and quantitative analysis

1 reference

12 December 2020

Protecting research subjects--the crisis at Johns Hopkins

1 reference

12 December 2020

A phase I, single and fractionated, ascending-dose study evaluating the safety, pharmacokinetics, pharmacodynamics, and immunogenicity of an erythropoietin mimetic antibody fusion protein (CNTO 528) in healthy male subjects

1 reference

12 December 2020

Use of biomarkers from drug discovery through clinical practice: report of the Ninth European Federation of Pharmaceutical Sciences Conference on Optimizing Drug Development

1 reference

12 December 2020

Use of biomarkers and surrogate endpoints in drug development and regulatory decision making: criteria, validation, strategies

1 reference

12 December 2020

Biomarkers for the effects of selective serotonin reuptake inhibitors (SSRIs) in healthy subjects

1 reference

12 December 2020

Pharmacokinetic differences between Caucasian and Japanese subjects after single and multiple doses of a potential combined oral contraceptive (Org 30659 and EE)

1 reference

12 December 2020

Pharmacodynamics and pharmacokinetics of a single oral dose of nitrazepam in healthy volunteers: an interethnic comparative study between Japanese and European volunteers

1 reference

12 December 2020

Biomarkers for the effects of antipsychotic drugs in healthy volunteers

1 reference

12 December 2020

Concentration-effect relationships of two rilmenidine single-dose infusion rates in hypertensive patients.

1 reference

12 December 2020

No evidence of the usefulness of eye blinking as a marker for central dopaminergic activity

1 reference

12 December 2020

Biomarkers for the effects of benzodiazepines in healthy volunteers

1 reference

12 December 2020

Model-based drug development

1 reference

12 December 2020

REM sleep effects as a biomarker for the effects of antidepressants in healthy volunteers

1 reference

12 December 2020

Evaluation of tests of central nervous system performance after hypoxemia for a model for cognitive impairment

1 reference

12 December 2020

Integrated pharmacokinetics and pharmacodynamics of Ro 48-6791, a new benzodiazepine, in comparison with midazolam during first administration to healthy male subjects

1 reference

12 December 2020

Learning versus confirming in clinical drug development

1 reference

12 December 2020

10.2165/00003088-200847060-00002

Identifiers

DOI

1 reference

Dimensions Publication ID

29 June 2017

1045739140

0 references

1 reference